All the news Showing 8 of 8 articles from: Side effectsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources FDA warns of rare cases of serious liver injury with newer hepatitis C drugs Keith Alcorn / 29 August 2019 The US Food and Drug Administration (FDA) has issued a warning about the risk of serious liver injury in people with hepatitis C after starting recently approved direct-acting antiviral regimens that contain ... Tenofovir alafenamide for hepatitis B shows improved kidney and bone safety after a year Liz Highleyman / 08 January 2019 Tenofovir alafenamide (TAF; Vemlidy), the new formulation of tenofovir, continues to appear at least equally effective for treatment of hepatitis B but with a better safety profile than the older tenofovir disoproxil fumarate ... Switching to TAF improves safety in people with hepatitis B with kidney and bone risk factors Liz Highleyman / 04 May 2018 People with risk factors for tenofovir toxicity who switched from tenofovir disoproxil fumarate (TDF; Viread) to the new tenofovir alafenamide (TAF; Vemlidy) maintained hepatitis B virus (HBV) suppression and showed evidence of improved kidney and ... Switching to TAF for hepatitis B improves kidney function and bone loss Liz Highleyman / 26 April 2017 People with hepatitis B who switched from the old tenofovir disoproxil fumarate (TDF) to the new tenofovir alafenamide (TAF) saw improvements in kidney function biomarkers and recovery of bone loss, researchers reported at ... Are New Drugs for Hepatitis C Safe? A Report Raises Concerns New York Times / 25 January 2017 New Tenofovir Formulation Provides Safer Hepatitis B Treatment Medscape (free registration required) / 03 October 2016 Tenofovir alafenamide works well against hepatitis B with less effect on bones and kidneys Liz Highleyman / 18 April 2016 The new tenofovir alafenamide (TAF) pro-drug is as potent against hepatitis B virus (HBV) as the current tenofovir disoproxil fumarate (TDF) formulation, but with fewer detrimental effects on bone and kidney biomarkers, ... Costs for Hepatitis C Treatment Skyrocket Medscape (requires registration) / 14 November 2013 ← First1Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive